Back to search results

Pre-operative Tumor Treating Fields for Lung Cancer

This study is looking at how a device called the NovoTTF-200T System affects patients with early-stage non-small cell lung cancer (NSCLC) before surgery. The NovoTTF-200T System uses low-intensity electrical fields to treat cancer. You might be able to join if you have stage I-IIIA NSCLC that can be removed by surgery, are at least 22 years old, and have a good performance status (meaning you can do most daily activities). The main goal is to see how the NovoTTF-200T System affects certain genes related to Fanconi anemia in your tumor after about 2 to 4 weeks of treatment. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 18 participants. It will look at the effects of the NovoTTF-200T System.
What's involved
You will have a blood sample taken, vital signs checked, a tumor tissue sample collected, and a tumor scan. You will have 5 scheduled clinic visits over a 2-month period.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at approximately 14-28 days after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06552000

Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer

Not Yet Recruiting
NAAges 22+InterventionalTreatment
University of Texas Southwestern Medical Center
~18 participants
Updated 2026-02-23 on ClinicalTrials.gov
What's tested:NovoTTF-200T System

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Effect of TTF (Tumor-Treating Fields) on Fanconi anemia-related genes.
Measured over approximately 14-28 days

Conditions

NSCLC
Non Small Cell Lung Cancer

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • John Waters, MD · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center

Who to contact

Ebele Mbanugo, Ed.D, CCRP
[email protected]
214-645-0326
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

6a. A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
• Has not undergone a hysterectomy or bilateral oophorectomy; or
• Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). 7. Age ≥22 years at time of screening.

What this trial measures

  • Effect of TTF (Tumor-Treating Fields) on Fanconi anemia-related genes.approximately 14-28 days

    Determine the effect of TTFields on expression of Fanconi anemia pathway-associated genes in NSCLC.